Research ArticleArticle
Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials
Lisa J. Herrinton, Liyan Liu, Robert Goldfien, M. Alex Michaels and Trung N. Tran
The Journal of Rheumatology July 2016, jrheum.150671; DOI: https://doi.org/10.3899/jrheum.150671
Lisa J. Herrinton
From the Division of Research, Kaiser Permanente Northern California; Department of Rheumatology, The Permanente Medical Group, Oakland, California; Patient Safety Department, AstraZeneca/MedImmune; Observational Research Center, AstraZeneca, Gaithersburg, Maryland, USA. Funded by AstraZeneca/Medimmune, Gaithersburg, Maryland, USA, under a contract with Medimmune to provide comparison information for evaluation of the safety of sifalimumab and anifrolumab. Medimmune requested the study. Operational definitions and programming code used in the study were developed in part from projects funded by the US Agency for Health Care Research and Quality (U18HS17919; R01HS021589) and the US National Institute of Allergy and Infectious Diseases (RC1AI086107). L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California; L. Liu, MD, Division of Research, Kaiser Permanente Northern California; R. Goldfien, MD, Department of Rheumatology, The Permanente Medical Group; M.A. Michaels, MD, Patient Safety Department, AstraZeneca/MedImmune; T.N. Tran, MD, PhD, Observational Research Center, AstraZeneca. Address correspondence to L.J. Herrinton, Division of Research, Kaiser Permanente, 2000 Broadway Ave., Oakland, California 94612, USA. E-mail: Lisa.Herrinton@kp.org. Accepted for publication April 20, 2016.
Liyan Liu
From the Division of Research, Kaiser Permanente Northern California; Department of Rheumatology, The Permanente Medical Group, Oakland, California; Patient Safety Department, AstraZeneca/MedImmune; Observational Research Center, AstraZeneca, Gaithersburg, Maryland, USA. Funded by AstraZeneca/Medimmune, Gaithersburg, Maryland, USA, under a contract with Medimmune to provide comparison information for evaluation of the safety of sifalimumab and anifrolumab. Medimmune requested the study. Operational definitions and programming code used in the study were developed in part from projects funded by the US Agency for Health Care Research and Quality (U18HS17919; R01HS021589) and the US National Institute of Allergy and Infectious Diseases (RC1AI086107). L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California; L. Liu, MD, Division of Research, Kaiser Permanente Northern California; R. Goldfien, MD, Department of Rheumatology, The Permanente Medical Group; M.A. Michaels, MD, Patient Safety Department, AstraZeneca/MedImmune; T.N. Tran, MD, PhD, Observational Research Center, AstraZeneca. Address correspondence to L.J. Herrinton, Division of Research, Kaiser Permanente, 2000 Broadway Ave., Oakland, California 94612, USA. E-mail: Lisa.Herrinton@kp.org. Accepted for publication April 20, 2016.
Robert Goldfien
From the Division of Research, Kaiser Permanente Northern California; Department of Rheumatology, The Permanente Medical Group, Oakland, California; Patient Safety Department, AstraZeneca/MedImmune; Observational Research Center, AstraZeneca, Gaithersburg, Maryland, USA. Funded by AstraZeneca/Medimmune, Gaithersburg, Maryland, USA, under a contract with Medimmune to provide comparison information for evaluation of the safety of sifalimumab and anifrolumab. Medimmune requested the study. Operational definitions and programming code used in the study were developed in part from projects funded by the US Agency for Health Care Research and Quality (U18HS17919; R01HS021589) and the US National Institute of Allergy and Infectious Diseases (RC1AI086107). L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California; L. Liu, MD, Division of Research, Kaiser Permanente Northern California; R. Goldfien, MD, Department of Rheumatology, The Permanente Medical Group; M.A. Michaels, MD, Patient Safety Department, AstraZeneca/MedImmune; T.N. Tran, MD, PhD, Observational Research Center, AstraZeneca. Address correspondence to L.J. Herrinton, Division of Research, Kaiser Permanente, 2000 Broadway Ave., Oakland, California 94612, USA. E-mail: Lisa.Herrinton@kp.org. Accepted for publication April 20, 2016.
M. Alex Michaels
From the Division of Research, Kaiser Permanente Northern California; Department of Rheumatology, The Permanente Medical Group, Oakland, California; Patient Safety Department, AstraZeneca/MedImmune; Observational Research Center, AstraZeneca, Gaithersburg, Maryland, USA. Funded by AstraZeneca/Medimmune, Gaithersburg, Maryland, USA, under a contract with Medimmune to provide comparison information for evaluation of the safety of sifalimumab and anifrolumab. Medimmune requested the study. Operational definitions and programming code used in the study were developed in part from projects funded by the US Agency for Health Care Research and Quality (U18HS17919; R01HS021589) and the US National Institute of Allergy and Infectious Diseases (RC1AI086107). L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California; L. Liu, MD, Division of Research, Kaiser Permanente Northern California; R. Goldfien, MD, Department of Rheumatology, The Permanente Medical Group; M.A. Michaels, MD, Patient Safety Department, AstraZeneca/MedImmune; T.N. Tran, MD, PhD, Observational Research Center, AstraZeneca. Address correspondence to L.J. Herrinton, Division of Research, Kaiser Permanente, 2000 Broadway Ave., Oakland, California 94612, USA. E-mail: Lisa.Herrinton@kp.org. Accepted for publication April 20, 2016.
Trung N. Tran
From the Division of Research, Kaiser Permanente Northern California; Department of Rheumatology, The Permanente Medical Group, Oakland, California; Patient Safety Department, AstraZeneca/MedImmune; Observational Research Center, AstraZeneca, Gaithersburg, Maryland, USA. Funded by AstraZeneca/Medimmune, Gaithersburg, Maryland, USA, under a contract with Medimmune to provide comparison information for evaluation of the safety of sifalimumab and anifrolumab. Medimmune requested the study. Operational definitions and programming code used in the study were developed in part from projects funded by the US Agency for Health Care Research and Quality (U18HS17919; R01HS021589) and the US National Institute of Allergy and Infectious Diseases (RC1AI086107). L.J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California; L. Liu, MD, Division of Research, Kaiser Permanente Northern California; R. Goldfien, MD, Department of Rheumatology, The Permanente Medical Group; M.A. Michaels, MD, Patient Safety Department, AstraZeneca/MedImmune; T.N. Tran, MD, PhD, Observational Research Center, AstraZeneca. Address correspondence to L.J. Herrinton, Division of Research, Kaiser Permanente, 2000 Broadway Ave., Oakland, California 94612, USA. E-mail: Lisa.Herrinton@kp.org. Accepted for publication April 20, 2016.
Article Figures & Data
Additional Files
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials
Lisa J. Herrinton, Liyan Liu, Robert Goldfien, M. Alex Michaels, Trung N. Tran
The Journal of Rheumatology Jul 2016, jrheum.150671; DOI: 10.3899/jrheum.150671